¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody-mediated cytotoxic hypersensitivity reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® hypersensitivity ÇÑ±Û °ú¹Î, ¿¹¹Î
¼³¸í   
  1. ¾î¶² ¾à¹°À̳ª Àڱؿ¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ. °ú¹Î¼º ¹ÝÀÀÀº ¸é¿ª¹ÝÀÀ¿¡ ÀÇÇÏ¿© »ý±â´Â º´Àû °úÁ¤À¸·Î, Áï½ÃÇü¹ÝÀÀ°ú Áö¿¬Çü¹ÝÀÀÀ¸·Î ºÐ·ùµÈ´Ù. ¶ÇÇÑ ´ÙÀ½ÀÇ 4ÇüÀ¸·Î ºÐ·ùµÇ±âµµ ÇÑ´Ù. IÇüÀº Áï½ÃÇü °ú¹Î¼º ¹ÝÀÀ(¿¹ÄÁ´ë anaphylaxis). IIÇüÀº Á¶Á÷Ç׿ø¿¡ ´ëÇÑ Ç×ü¿¡ ÀÇÇÏ¿© »ý±â´Â ¼Õ»ó(¿¹ÄÁ´ë ÄáÆÏµ¶¼º ÄáÆÏ¿°). IIIÇüÀº Ç׿øÇ×üº¹ÇÕ¹°, Æ¯È÷ ¾à°£ÀÇ Ç׿øÀÇ °úÀ׿¡ ÀÇÇÏ¿© Çü¼ºµÇ´Â ¿ëÇØ¼º º¹ÇÕ¹°¿¡ ÀÇÇÏ¿© »ý±â´Â °Í(¿¹ÄÁ´ë ¾Æ¸£Åõ½º ¹ÝÀÀÀ̳ª Ç÷ûº´). IVÇüÀº Áö¿¬Çü °ú¹Ì¼º ¹ÝÀÀ(¿¹ÄÁ´ë Á¢Ã˼º ÇǺκ´)ÀÌ´Ù. 2. °¨°¢À̳ª °¨Á¤ÀÌ Áö³ªÄ¡°Ô ¿¹¹ÎÇÔ.
¿µ¹® immunological reaction ÇÑ±Û ¸é¿ª¹ÝÀÀ
¼³¸í   
  »ýüÀÇ ¸ö ¾È¿¡¼­ »ý±ä ¹°ÁúÀ̳ª ¸ö ¹Û¿¡¼­ µé¾î¿Â ¹°ÁúÀÌ »ýü¿Í ´Ù¸¦ ¶§ ÀÚ±â Ã¼³»ÀÇ ÅëÀϼº°ú °³Ã¼ÀÇ »ýÁ¸ À¯Áö ¹× Á¾ÀÇ Á¸¼ÓÀ» À§ÇÏ¿© ±× ¹°ÁúµéÀ» Á¦°ÅÇϴ ÀÏ·ÃÀÇ »ýü ¹ÝÀÀ. ´Ù½Ã ¸»ÇØ B¼¼Æ÷¿¡ ÀÇÇÑ Ç×ü»ý»ê, T¼¼Æ÷¸¦ Áß½ÉÀ¸·Î Çϴ ¼¼Æ÷¼º ¸é¿ª, ¸é¿ª°ü¿ë, ¸é¿ª±â¾ï µîÀÇ »ýü ³» ¹ÝÀÀÀ» ¸»ÇÑ´Ù. Å«Æ÷½Ä¼¼Æ÷´Â Ç׿øÀ» Ã³¸®Çؼ­ Æ¯ÀÌÀûÀΠÇ׿ø°áÁ¤±â¸¦ °®´Â ºÐÀڷΠ¹Ù²ã, Ç׿ø°ú ÁÖ¿äÁ¶Á÷ ÀûÇÕÀ¯ÀüÀÚº¹ÇÕü¸¦ ¼¼Æ÷Ç¥¸é¿¡ Ç¥ÇöÇϸç, T¼¼Æ÷·Î Àü´ÞÇÑ´Ù. ÇÑÆí B¼¼Æ÷´Â Å«Æ÷½Ä¼¼Æ÷ ³»¿¡¼­ Ã³¸®µÈ Ç׿øÀÇ °áÁ¤±â¸¦ ÀνÄÇÏ¿© ´ëÀÀÇϴ ƯÀÌÀûÇ×ü¸¦ »ý»êÇÏ¿© Ç׿øÀ» Ã³¸®ÇÑ´Ù. 
¿µ¹® reaction formation ÇÑ±Û ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º
¼³¸í   
  ¾ï¾Ðº¸´Ù ´õ Àû±ØÀûÀΠ¹æ¾î¸ÞÄ¿´ÏÁòÀ̸ç, ¹«ÀǽÄÀûÀΠ»ý°¢, ¼Ò¿ø, Ã浿ÀÌ ³Ê¹«³ªµµ ¹Þ¾Æµé¿©Áú ¼ö ¾ø´Â °ÍÀÏ °æ¿ì¿¡ À̿ʹ Á¤¹Ý´ë ¹æÇâÀÇ °ÍÀ» °­Á¶ÇÔÀ¸·Î½á ±×·± ¹«ÀǽÄÀûÀΠ°ÍµéÀÌ ÀǽĵÇÁö ¾Ê°Ô Çϴ °úÁ¤. ¿¹¸¦ µé¸é °¡Àå °¡ÇÐÀûÀΠ¼º°ÝÀÇ »ç¶÷ÀÌ »ýÃ¼ÇØºÎ ¹Ý´ë·ÐÀÚ°¡ µÇ´Â °æ¿ì¸¦ µé ¼ö ÀÖ´Ù. À̰ÍÀº ¶Ç °¡½¿ ±íÀÌ Àá°ÜÀִ µÎ·Á¿òÀÌ ÀǽĵǴ °ÍÀ» ÇÇÇϱâ À§Çؼ­ µÎ·Á¿òÀÇ ´ë»óÀÌ µÇ´Â Çൿ¿¡ °ñ¸ôÇϴ °æ¿ìµµ Æ÷ÇÔÀÌ µÈ´Ù. ¿¹¸¦ µé¸é, ³²ÀÚ¿¡°Ô »óó¹ÞÁö ¾ÊÀ»±î Çϴ µÎ·Á¿ò¿¡ °¡µæ Âù ¼Ò³à°¡ ÀÌ °°Àº µÎ·Á¿òÀ» ºÎÁ¤ÇÏ·Á´Â ¼ö´ÜÀ¸·Î ³­ÀâÇÑ ¼ºÇàÀ§¿¡ °ñ¸ôÇϴ °æ¿ì°¡ ÀÖ´Ù. ¶Ç ÀüóÀÇ Àڳฦ ¹Ì¿öÇϴ °è¸ð°¡ ¿ÀÈ÷·Á Áö³ªÄ¥ Á¤µµ·Î ±× ¾ÆÀ̸¦ ±Í¿©¿öÇϴ ÀÏ µûÀ§ÀÌ´Ù. 
¿µ¹® complement fixation reaction ÇÑ±Û º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
¼³¸í   
  Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ À־ º¸Ã¼¿Í °áÇÕÇϴ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼­´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇϴ ¿ëÇ÷¼ÒÀǠȥÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀϾ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼­ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉí, Å¬¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ.
  
  
¿µ¹® transfusion reaction ÇÑ±Û ¼öÇ÷ºÎÀÛ¿ë, ¼öÇ÷¹ÝÀÀ
¼³¸í   
  ¼öÇ÷ÇÏ¿´À» ¶§¿¡ È¯ÀÚ¿¡°Ô ÀϾ´Â ¹ÝÀÀ. ¾Ë·¹¸£±â ¹ÝÀÀ°ú ¿ëÇ÷ ¹ÝÀÀÀÌ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic hypersensitivity
    ¼¼Æ÷µ¶¼º°ú¹Î¼º
  • cytotoxic reaction
    ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • cytotoxic
    ¼¼Æ÷µ¶¼º-
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic chemotherapy
    ¼¼Æ÷µ¶¼ºÈ­Çпä¹ý
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • cytotoxic edema
    ¼¼Æ÷µ¶¼ººÎÁ¾
  • cytotoxic hypoxia
    ¼¼Æ÷µ¶¼ºÀú»ê¼ÒÁõ
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • atopic hypersensitivity
    ¾ÆÅäÇǰú¹Î¼º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic chemotherapy
    Ç×¾ÏÈ­Çпä¹ý
  • hypersensitivity
    °ú¹Î
  • reaction formation
    ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º
  • reaction fever
    ¹ÝÀÀ¿­
  • reaction
    ¹ÝÀÀ
  • adjustment reaction
    ÀûÀÀ¹ÝÀÀ
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ
  • allergic reaction
    ¾Ë·¹¸£±â¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • anxiety reaction
    ºÒ¾È¹ÝÀÀ
  • cascade reaction
    ¿¬¼âÁõÆø¹ÝÀÀ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • complement fixation reaction
    µµ¿òü°áÇÕ¹ÝÀÀ, º¸Ã¼°áÇÕ¹ÝÀÀ
  • cross reaction
    ±³Â÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic hypersensitivity
    ¼¼Æ÷µ¶¼º°ú¹Î
  • cytotoxic reaction
    µ¶¼º¹ÝÀÀ, ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic
    ¼¼Æ÷µ¶¼º-
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • cytotoxic edema
    ¼¼Æ÷µ¶¼ººÎÁ¾
  • cytotoxic hypoxia
    ¼¼Æ÷µ¶¼ºÀú»ê¼ÒÁõ
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹é
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î
  • atopic hypersensitivity
    ¾ÆÅäÇǰú¹Î
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
  • contact hypersensitivity
    Á¢Ã˰ú¹Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cytotoxic
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ)
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • angiitis,hypersensitivity
    °ú¹Î¼º(ΦÚÂàõ)
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³ °ú¹Î¹ÝÀÀ
  • gluten hypersensitivity
    ±Û·çÅÙ°ú¹Î¹ÝÀÀ
  • hypersensitivity
    °ú¹Î¼º
  • hypersensitivity
    °¨°¢°ú¹Î¼º
  • hypersensitivity =hypersensitiveness
    °ú¹Î¼º, °ú¹ÎÁõ.
  • hypersensitivity angitis
    °ú¹Î¼º ¸Æ°ü¿°.
  • hypersensitivity angitis
    °ú¹Î¼º Ç÷°ü¿°(ΦÚÂàõ úìηæú)
  • hypersensitivity disorders
    °ú¹Î¼º Áúȯ(ΦÚÂàõ òðü´)
  • hypersensitivity myocarditis
    °ú¹Î¼º ½É±Ù¿°.
  • hypersensitivity pneumonia
    °ú¹Î¼º Æó·Å.
  • hypersensitivity reactions
    °ú¹Î¼º ¹ÝÀÀ(ΦÚÂàõ Úãëë)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic reaction
    ¼¼Æ÷µ¶¼º¹ÝÀÀ.
  • cytotoxic reaction
    µ¶¼º¹ÝÀÀ.
  • cytotoxic reaction
    ¼¼Æ÷ µ¶¼º ¹ÝÀÀ
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic
    <¾à¹°>, ¼¼Æ÷µ¶¼º(¡­Ô¸àõ)ÀÇ.
  • cytotoxic
    ¼¼Æ÷µ¶¼º(¡­Ô¸àõ)ÀÇ.
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º T ¼¼Æ÷
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼ºT¼¼Æ÷
  • cytotoxic T lymphocyte (CTL)
    ¼¼Æ÷µ¶¼ºT¸²ÇÁ±¸
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • cytotoxic action
    ¼¼Æ÷µ¶ÀÛ¿ë.
  • cytotoxic agent
    ¼¼Æ÷ µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü.
  • cytotoxic antibody
    °ú¼¼Æ÷µ¶Ç×ü, ¼¼Æ÷µ¶¼ºÇ×ü.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Reaction deficiency
    ¹ÝÀÀ°áÇÌ
    [¿¾ ¿ë¾î] ¹ÝÀÀ°áÇÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic anaphylaxis
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) ¾Æ³ªÇʶô½Ã½º
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼º Ç×ü(á¬øàÔ¸àõù÷ô÷)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • contact hypersensitivity
    Á¢Ã˰ú¹ÎÁõ(ïÈõºÎ¦ÚÂñø)
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹ÎÁõ(òÀæÅû¡Î¦ÚÂñø)
  • hypersensitivity
    °ú¹Î¼º(ΦÚÂàõ)
  • immediate-type hypersensitivity
    Áï½ÃÇü °ú¹ÎÁõ(ñíãÁúþΦÚÂñø)
  • induced hypersensitivity
    À¯µµ°ú¹ÎÁõ(ë¯ÓôΦÚÂñø)
  • spontaneous hypersensitivity
    ÀÚ¿¬ °¨¼ö¼º(í»æÔÊïáôàõ)
  • tuberculin hypersensitivity
    Åõº£¸£Ä𸰠°ú¹Î¼º(ΦÚÂàõ)
  • absolute reaction rates
    Àý´ë¹ÝÀÀ¼Óµµ (ï¾ÓßÚãëëáÜÓø)
  • abstraction reaction
    Á¦°Å¹ÝÀÀ (ð¶ËÛÚãëë)
  • Adamkiewicz reaction
    ¾Æ´ãŰºñÃ÷ ¹ÝÀÀ(Úãëë)
  • addition reaction
    ºÎ°¡¹ÝÀÀ(ݾʥÚãëë)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic
    ¼¼Æ÷µ¶¼º ¹°Áú, ¼¼Æ÷µ¶¼ºÀÇ
  • hypersensitivity
    °ú¹Î¼º, °ú¹ÎÁõ
  • adverse reaction
    ºÎÀÛ¿ë, À¯ÇعÝÀÀ, À¯ÇØÀÛ¿ë, ¿ª¹ÝÀÀ
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • desmoid reaction
    Àδë¾ç¹ÝÀÀ
  • glial reaction
    ±³¼¼Æ÷ÀÛ¿ë,½Å°æ±³ÀÛ¿ë
  • hypersensitive reaction
    °ú¹Î¼º¹ÝÀÀ
  • leukemoid reaction
    ¹éÇ÷º´¾ç ¹ÝÀÀ
  • periosteal reaction
    °ñ¸·¹ÝÀÀ
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ
  • reaction
    ¹ÝÀÀ
  • side reaction
    ºÎÀÛ¿ë, ºÎ¹ÝÀÀ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LR labeled release; laboratory references; laboratory report; labor room; lactated Ringer [solution]; l...
DHR delayed hypersensitivity reaction; Department of Human Resources
DSHR delayed skin hypersensitivity reaction
GHR granulomatous hypersensitivity reaction
AAR active avoidance reaction; acute articular rheumatism; antigen-antiglobulin reaction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DTH Delayed type hypersensitivity reaction
CSH Carotid sinus hypersensitivity
CH Contact hypersensitivity
CHS Contact hypersensitivity
CBH Cutaneous basophil hypersensitivity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cytotoxic
    ¼¼Æ÷ µ¶¼º
    ¼¼Æ÷ µ¶¼Ò¿¡ ÀÇÇÑ. ¼¼Æ÷ µ¶ ÀÛ¿ëÀ» Áö´Ñ.
  • cytotoxic antibody
    ¼¼Æ÷ µ¶ Ç×ü, ¼¼Æ÷ µ¶¼º Ç×ü
  • cytotoxic factor
    ¼¼Æ÷ µ¶¼º ÀÎÀÚ
  • cytotoxic substance
    ¼¼Æ÷ µ¶, ¼¼Æ÷µ¶¼Ò
    µ¿ÀǾî=cytotoxin.
  • humoral cytotoxic antibody
    ü¾×¼º ¼¼Æ÷ µ¶¼º Ç×ü
  • T cell cytotoxic
    T ¼¼Æ÷ µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cutaneous hypersensitivity
    ÇǺΠ°ú¹ÎÁõ
  • delayed hypersensitivity
    Áö¿¬Çü °ú¹Î¼º
  • denervation hypersensitivity test
    Å»½Å°æ °ú¹Î ¹ÝÀÀ °Ë»ç
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • hypersensitivity angitis
    °ú¹Î¼º ¸Æ°ü¿°
  • immediate hypersensitivity
    Áï½Ã °ú¹ÎÁõ, Áï½ÃÇü °ú¹ÎÁõ, Áï°¢ °ú¹Î ¹ÝÀÀ
    ¹Ì¸® ƯÁ¤ÀÇ Ç׿ø¿¡ ÀÇÇÏ¿© °¨À۵ǰí ÀÖ´Â »ýü°¡ µ¿ÀÏ Ç׿øÀÇ 2ȸ ° ÀÌÈÄÀÇ Åõ¿©¿¡ ÀÇÇÏ¿© Á¤»óº¸´Ù °ú¹ÎÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å²´Ù. À̶§ÀÇ ¹ÝÀÀÀ¸·Î ÀÌ Ç׿ø°ú »ýü ³»¿¡ »ý»êµÈ Ç×ü¿¡ ÀÇÇÏ¿© ƯÀÌÀûÀÎ °áÇÔÀÌ ÀϾ »ýüÁ¶Á÷¿¡ Àå¾Ö¸¦ ÀÏÀ¸Å²´Ù.
  • streptococcal hypersensitivity
    ¿¬¼â ±¸±Õ °ú¹Î¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cytotoxic reaction An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement.
(05 Mar 2000)
hypersensitivity reaction <immunology> The bodys response to an allergic stimulus. This can be localised to one area or generalised and may include: rash, itching, hives, swelling, difficulty breathing, and/or low blood pressure.
(27 Sep 1997)
immediate hypersensitivity reaction An immune response mediated by antibody, usually IgE, which occurs within minutes after a second encounter with an antigen, resulting in the release of histamine and subsequent swelling and vasodilation.
(05 Mar 2000)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
antireticular cytotoxic serum An antiserum specific for cells of the reticuloendothelial system.
(05 Mar 2000)
cytotoxic <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration.
(16 Dec 1997)
cytotoxic cell Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells.
Synonym: cytotoxic cell.
(05 Mar 2000)
cytotoxic drugs <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells.
See: chemotherapy.
(13 Nov 1997)
cytotoxic T-cell <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens).
(18 Nov 1997)
cytotoxic t-lymphocyte A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene:
See: Ganciclovir.
(09 Oct 1997)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
T cytotoxic cells Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors.
(12 Dec 1998)
T-lymphocytes, cytotoxic Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity.
(12 Dec 1998)
vasculitis, hypersensitivity Heterogeneous group of disorders characterised by a vasculitic syndrome presumed to be associated with a hypersensitivity reaction following exposure to an antigen such as an infectious agent, a drug, or other foreign or endogenous substance.
(12 Dec 1998)
respiratory hypersensitivity A form of hypersensitivity affecting the respiratory tract. It includes asthma and hay fever.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypersensitivity
    °ú¹ÎÁõ
  • reaction
    ¹Ýµ¿
  • Feulgen reaction
    Æ÷ÀϰÕ(ÇÙ¿°»ö)¹ÝÀÀ
  • GVH reaction
    ´ë¼÷ÁÖ ÀÌ½ÄÆí ¹ÝÀÀ(ÀÌ½ÄµÈ Àå±â¿Í ü³» ¸é¿ª ¼¼Æ÷°£ÀÇ ¹ÝÀÀ)
  • atomic reaction
    ¿øÇÙ ¹ÝÀÀ
  • atonic reaction
    ¿øÀÚÇÙ¹ÝÀÀ
  • chain reaction
    ¿¬¼â ¹ÝÀÀ;(»ç°Ç µîÀÇ)¿¬¼â ¹ÝÀÀ
  • dark reaction
    (½Ä)¾Ï¹ÝÀÀ
  • exchange reaction
    (¹°)±³È¯ ¹ÝÀÀ
  • fightorfight reaction
    ¹æÀ§ ¹ÝÀÀÀÇ ÀÏÁ¾
  • fission chain reaction
    Çٺп­ ¿¬¼â ¹ÝÀÀ
  • fusion reaction
    ÇÙÀ¶ÇÕ ¹ÝÀÀ
  • nuclear reaction
    ÇÙ¹ÝÀÀ
  • protective reaction
    ¹æ¾î ¹ÝÀÀ(ÀÚÀ§,º¸º¹À» ¸ñÀûÀ¸·Î ÇÑ Æø°Ý)
  • reaction
    ¹ÝÀÛ¿ë;¹ÝÇ×;¹Ý¹ß;(Á¤Ä¡»óÀÇ)¹Ýµ¿;¿ªÇà;(ÀÚ±Ø.»ç°Ç.¿µÇ⠵ ´ëÇÑ)¹ÝÀÀ;ŵµ;Àǰß;Àλó;(°ú·Î.±äÀå.ÈïºÐ ÈÄÀÇ)Ȱ·Â°¨Åð;¹«±â·Â;¹ÝÀÀ;¹ÝÀÛ¿ë;¹Ýµ¿·Â;ÇÙ¹ÝÀÀ;¹ÝÃæ ÀÛ¿ë;Àç»ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á